MINERVA OPINION EDITORIAL   Free access

Minerva Urology and Nephrology 2023 August;75(4):419-21

DOI: 10.23736/S2724-6051.23.05347-8

Copyright © 2023 EDIZIONI MINERVA MEDICA

language: English

Prognostic models for patients with metastatic urothelial carcinoma: why use them?

Michele MAFFEZZOLI ¹ ✉, Davide CAMPOBASSO ², Sara E. REBUZZI ^{3, 4}, Giuseppe L. BANNA ⁵, Giuseppe FORNARINI ⁶, Alessio SIGNORI ⁷, Pasquale RESCIGNO ⁸, Sebastiano BUTI ^{1, 9}

¹ Unit of Medical Oncology, University Hospital of Parma, Parma, Italy; ² Department of Urology, University Hospital of Parma, Parma, Italy; ³ Unit of Medical Oncology, San Paolo Hospital, Savona, Italy; ⁴ Department of Internal Medicine and Medical Specialties (Di.M.I.), University of Genoa, Genoa, Italy; ⁵ Department of Oncology, Portsmouth Hospitals University NHS Trust, Portsmouth, UK; ⁶ Unit of Medical Oncology, IRCCS San Martino University Hospital, Genoa, Italy; ⁷ Section of Biostatistics, Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy; ⁸ Center for Cancer, Translational and Clinical Research Institute, Newcastle University, Newcastle Upon Tyne, UK; ⁹ Department of Medicine and Surgery, University of Parma, Parma, Italy